We're off to the races!

FDA Approves Baxter's Prophylaxis Treatment of Hemophilia B

FDA Approves Baxter’s RIXUBIS as First Recombinant Factor IX Treatment for Routine Prophylaxis of Hemophilia BApproval brings patients first new rFIX treatment option in more than 15 yearsDEERFIELD, Ill.–(BUSINESS WIRE)– Baxter International Inc. (NYS: BAX) today announced that the United States Food and Drug Administration (FDA) has approved RIXUBIS [Coagulation Factor IX (Recombinant)] for routine […]

en_USEnglish